Black FridayUp to 80% OFF
Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪880.39 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
44.27
Basic EPS (TTM)
0.31 USD
Net income (FY)
‪−72.70 M‬ USD
Revenue (FY)
‪75.62 M‬ USD
Shares float
‪42.21 M‬
Beta (1Y)
1.35

Employees


Employees (FY)
134
Change (1Y)
+1 +0.75%
Revenue / Employee (1Y)
‪564.34 K‬ USD
Net income / Employee (1Y)
‪−542.54 K‬ USD

About Monte Rosa Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Markus Warmuth
Website
monterosatx.com
Headquarters
Boston
Founded
2019
ISIN
US61225M1027
FIGI
BBG00X2VGZQ3
IPO date
Jun 24, 2021
IPO offer price
19.00 USD
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Check out other big names from the same industry as GLUE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


IWM
iShares Russell 2000 ETF
Weight
0.02%
Market value
‪15.25 M‬
USD
AVUV
Avantis U.S. Small Cap Value ETF
Weight
0.04%
Market value
‪7.82 M‬
USD
IWN
iShares Russell 2000 Value ETF
Weight
0.05%
Market value
‪5.36 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.04%
Market value
‪3.69 M‬
USD
BSVO
EA Bridgeway Omni Small-Cap Value ETF
Weight
0.13%
Market value
‪2.22 M‬
USD
AVSC
Avantis U.S Small Cap Equity ETF
Weight
0.09%
Market value
‪1.65 M‬
USD
IWC
iShares Micro-Cap ETF
Weight
0.16%
Market value
‪1.51 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.01%
Market value
‪1.43 M‬
USD
PRFZ
Invesco RAFI US 1500 Small-Mid ETF
Weight
0.04%
Market value
‪892.44 K‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.07%
Market value
‪552.44 K‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.07%
Market value
‪552.44 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of GLUE is 14.22 USD — it has increased by 4.22% in the past 24 hours. Watch Monte Rosa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monte Rosa Therapeutics, Inc. stocks are traded under the ticker GLUE.
GLUE stock has risen by 0.14% compared to the previous week, the month change is a 46.47% rise, over the last year Monte Rosa Therapeutics, Inc. has showed a 70.30% increase.
We've gathered analysts' opinions on Monte Rosa Therapeutics, Inc. future price: according to them, GLUE price has a max estimate of 20.00 USD and a min estimate of 13.00 USD. Watch GLUE chart and read a more detailed Monte Rosa Therapeutics, Inc. stock forecast: see what analysts think of Monte Rosa Therapeutics, Inc. and suggest that you do with its stocks.
GLUE reached its all-time high on Sep 7, 2021 with the price of 45.56 USD, and its all-time low was 2.44 USD and was reached on Oct 25, 2023. View more price dynamics on GLUE chart.
See other stocks reaching their highest and lowest prices.
GLUE stock is 8.36% volatile and has beta coefficient of 1.35. Track Monte Rosa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Monte Rosa Therapeutics, Inc. there?
Today Monte Rosa Therapeutics, Inc. has the market capitalization of ‪925.98 M‬, it has increased by 16.33% over the last week.
Yes, you can track Monte Rosa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Monte Rosa Therapeutics, Inc. is going to release the next earnings report on Mar 12, 2026. Keep track of upcoming events with our Earnings Calendar.
GLUE earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.35 USD resulting in a 5.11% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Monte Rosa Therapeutics, Inc. earnings.
Monte Rosa Therapeutics, Inc. revenue for the last quarter amounts to ‪12.80 M‬ USD, despite the estimated figure of ‪9.23 M‬ USD. In the next quarter, revenue is expected to reach ‪15.55 M‬ USD.
GLUE net income for the last quarter is ‪−27.08 M‬ USD, while the quarter before that showed ‪−12.29 M‬ USD of net income which accounts for −120.26% change. Track more Monte Rosa Therapeutics, Inc. financial stats to get the full picture.
No, GLUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2025, the company has 134 employees. See our rating of the largest employees — is Monte Rosa Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Monte Rosa Therapeutics, Inc. EBITDA is ‪16.84 M‬ USD, and current EBITDA margin is −96.52%. See more stats in Monte Rosa Therapeutics, Inc. financial statements.
Like other stocks, GLUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monte Rosa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monte Rosa Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monte Rosa Therapeutics, Inc. stock shows the strong buy signal. See more of Monte Rosa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.